| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/21/2005 | US20050158393 Polymeric material associated with colloidal metal particles, especially gold, suitable for injection or implantation |
| 07/21/2005 | US20050158392 Drug delivery, sustained release, time-release agents |
| 07/21/2005 | US20050158391 Molten mixture allows the carrier to wet the entire surface of the azithromycin drug crystals allowing the crystals to be fully encapsulated |
| 07/21/2005 | US20050158390 Hollow nanoparticles; self-assembly; polyelectrolyte eg polyamine |
| 07/21/2005 | US20050158389 Microemulsion; increased stability; delivery system with high bioavailability of water insoluble substances |
| 07/21/2005 | US20050158388 Treatment of gynecomastia with 4-hydroxy tamoxifen |
| 07/21/2005 | US20050158387 Olopatadine formulations for topical administration |
| 07/21/2005 | US20050158386 Process for producing a pharmaceutical solid preparation containing a poorly soluble drug |
| 07/21/2005 | US20050158385 Multilayer dosage form; fast releasing dosage forms and slow releasing dosage forms; tablets |
| 07/21/2005 | US20050158384 Sustained release delivery of amphetamine salts |
| 07/21/2005 | US20050158383 Quetiapine hemifumarate; sustained release and pulsed release dosage; schizophenia and neuropsychiatric disorders |
| 07/21/2005 | US20050158382 Hydrocodone and acetaminophen; twice-a-day administration; pain relievers |
| 07/21/2005 | US20050158381 Sufficient to decrease the measurable amount of bacteria present in the urine of an individual having a urinary tract infection |
| 07/21/2005 | US20050158380 Sustained release oral dosage forms of gabapentin |
| 07/21/2005 | US20050158379 Minimization of drug oxidation in drug irradiated excipients formulations |
| 07/21/2005 | US20050158378 contacting liquid comprising solvents, binder and desmopressin acetate, with powders comprising excipients, carriers, diluent or mixtures, within a fluid bed granulation apparatus, selecting air flow, processing temperature and time, then mixing, shearing and compression to tablets; granulation |
| 07/21/2005 | US20050158377 Oral administion; useful for treating children or patients of at least 55 years of age |
| 07/21/2005 | US20050158376 Dietary supplement and method of processing same |
| 07/21/2005 | US20050158375 Improved residence time in the blood and migration into tumor cells; reduced accumulation in the heart |
| 07/21/2005 | US20050158374 Compositions and dosage forms for enhanced absorption of metformin |
| 07/21/2005 | US20050158373 Method and carrier complexes for delivering molecules to cells |
| 07/21/2005 | US20050158372 Immunoliposome-nucleic acid amplification (ILNAA) assay |
| 07/21/2005 | US20050158371 Ointment, cream containing SMP-114 or leflunomide; N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; antiinflammatory or antirheumatic |
| 07/21/2005 | US20050158368 Has a porous structure and a thin layer of detergent or thin coating of soap on the surface of the bathing substance preferably by spraying; use after wetting; disposable; one time use |
| 07/21/2005 | US20050158367 Liquid compositions comprising one or more medicaments |
| 07/21/2005 | US20050158365 Drug delivery device with mechanical locking mechanism |
| 07/21/2005 | US20050158362 Polymeric, fiber matrix delivery systems for bioactive compounds |
| 07/21/2005 | US20050158356 inhibits scarring that may otherwise occur when the pumps and sensors are implanted; antiscarring agent such as a cell cycle inhibitor |
| 07/21/2005 | US20050158348 Eutectic mixture of camphor, menthol, thymol and similar compounds is a powerful solvent for non-steroidal anti-inflammatory drugs; transdermal drug delivery of e.g. indomethacin, diclofenac, or ketoprofen |
| 07/21/2005 | US20050158330 water in oil in water (w/o/w) emulsion; polyethylene glycol outer aqueous phase; low viscosity for easier injection; storage stability; less topical response at the injection site; high immunological effect |
| 07/21/2005 | US20050158271 Copolymer of hydrophilic monomers and hydrophobic monomers which have a pendant hydrotropic moiety; hydrotropic polymer micelle has nanometer scale size, can deliver poorly soluble drugs, Paclitaxel, to the body |
| 07/21/2005 | US20050158250 Granulated composition of soluble, powdered insulin and a carrier of aggregated crystalline cellulose; increases a blood insulin concentration |
| 07/21/2005 | US20050158249 Therapeutic, prophylactic or diagnostic agent and biodegradable polymer; deposited after the first bifurcation of the lungs |
| 07/21/2005 | US20050158248 Method of preparing dry powder inhalation compositions |
| 07/21/2005 | US20050158247 [Tris(hydroxymethyl) aminomethane] as a selective absorbefacient, a therapeutically effective amount of active nasal peptide, in an aqueous liquid diluent; administered through the nasal mucosa-lined-epithelium |
| 07/21/2005 | US20050155601 Sublingual drug delivery device |
| 07/21/2005 | US20050155541 Preparation of small crystals |
| 07/21/2005 | US20050155519 Corn starch particles having enzyme resistance when administered in the mouth, formed by mixing binders, solvents, starches and artificial sweeteners, then sieving and drying; time-release agents for glucose; antidiabetic agents |
| 07/21/2005 | DE19901683B4 Analgetikum mit kontrollierter Wirkstofffreisetzung Analgesic with controlled release of active ingredient |
| 07/21/2005 | DE10359792A1 Mehrphasige Wirkstoffformulierung A multi-phase drug formulation |
| 07/21/2005 | DE10359790A1 Brausezubereitung einer basischen arzneilich wirksamen Substanz Effervescent formulation of a basic biological active substance |
| 07/21/2005 | CA2592867A1 Treatment |
| 07/21/2005 | CA2553943A1 Oxidative reductive potential water solution, processes for producing same and methods of using the same |
| 07/21/2005 | CA2552909A1 Pharmaceuticals for topical application in animals |
| 07/21/2005 | CA2552641A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| 07/21/2005 | CA2552632A1 Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer |
| 07/21/2005 | CA2552630A1 Non-disintegrating oral solid composition of high dose of water soluble drugs |
| 07/21/2005 | CA2552627A1 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent |
| 07/21/2005 | CA2552440A1 Pharmaceutical composition |
| 07/21/2005 | CA2552221A1 Donepezil formulations |
| 07/21/2005 | CA2552139A1 Medicinal compositions and method for the preparation thereof |
| 07/21/2005 | CA2552126A1 Ziprasidone formulations |
| 07/21/2005 | CA2552114A1 Solid dosage formulations of galantamine |
| 07/21/2005 | CA2552064A1 Atomoxetine formulations |
| 07/21/2005 | CA2551946A1 Immediate, controlled and sustained release formulations of galantamine |
| 07/21/2005 | CA2551900A1 Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors |
| 07/21/2005 | CA2551826A1 Inhalant formulation containing sulfoalkyl ether .gamma.-cyclodextrin and corticosteroid |
| 07/21/2005 | CA2551825A1 Drug granule coatings that impart smear resistance during mechanical compression |
| 07/21/2005 | CA2551815A1 Novel drug compositions and dosage forms |
| 07/21/2005 | CA2551749A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 07/21/2005 | CA2551530A1 Intranasal administration of glucose-regulating peptides |
| 07/21/2005 | CA2551528A1 Enteric coated aliphatic amine polymer bile acid sequestrants |
| 07/21/2005 | CA2551525A1 Pharmaceutical composition for thrombin peptide derivatives |
| 07/21/2005 | CA2551254A1 Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers |
| 07/21/2005 | CA2550699A1 Novel drug compositions and dosage forms of topiramate |
| 07/21/2005 | CA2550697A1 Drug delivery device with mechanical locking mechanism |
| 07/21/2005 | CA2549731A1 Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
| 07/21/2005 | CA2548403A1 Drug delivery device |
| 07/21/2005 | CA2548376A1 Solid compositions of low-solubility drugs and poloxamers |
| 07/21/2005 | CA2548179A1 Methods and compositions for the production of monoclonal antibodies |
| 07/21/2005 | CA2547712A1 Non-aqueous composition for oral delivery of insoluble bioactive agents |
| 07/21/2005 | CA2532207A1 Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| 07/20/2005 | EP1555278A1 Biodegradable multi-block co-polymers |
| 07/20/2005 | EP1555031A1 Angiogenesis inducer |
| 07/20/2005 | EP1555030A1 Sustained release preparation for treating coronary stenosis or obstruction |
| 07/20/2005 | EP1555025A2 Use of dehydroepiandrosterone analogs for the treatment of asthma |
| 07/20/2005 | EP1555024A1 Antibacterial medicinal composition of enhanced oral absorptivity |
| 07/20/2005 | EP1555023A2 Injectable buprenorphine microparticle compositions and their use |
| 07/20/2005 | EP1555022A1 Sustained release compound of acetamidophenol and tramadol |
| 07/20/2005 | EP1554936A1 Ketoprofen-supplemented animal feed and use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain |
| 07/20/2005 | EP1553974A1 Pharmaceutical composition comprising carriers for products |
| 07/20/2005 | EP1553957A1 Bisphosphonates for the treatment of atherosclerosis and devices comprising them |
| 07/20/2005 | EP1553956A2 Formulation for lipophilic agents |
| 07/20/2005 | EP1553954A2 Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 07/20/2005 | EP1553953A1 Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
| 07/20/2005 | EP1553945A2 Nitroxide radioprotector formulations and methods of use |
| 07/20/2005 | EP1553935A2 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer |
| 07/20/2005 | EP1553930A1 Capsule and film-forming composition comprising gum arabic |
| 07/20/2005 | EP1553929A2 Controlled release preparation |
| 07/20/2005 | EP1553928A1 Oral pharmaceutical compositions of fenofibrate having high bioavailability |
| 07/20/2005 | EP1553927A2 Gel-stabilized nanoparticulate active agent compositions |
| 07/20/2005 | EP1553926A2 Surface dissolution and/or bulk erosion controlled release compositions and devices |
| 07/20/2005 | EP1553925A1 Modified release oral dosage form |
| 07/20/2005 | EP1553924A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 07/20/2005 | EP1553923A1 Camptothecin-carboxylate formulations |
| 07/20/2005 | EP1553922A1 Salmeterol superfine formulation |
| 07/20/2005 | EP1553920A1 Topical formulation for prevention and treatment of acne |
| 07/20/2005 | EP1553910A1 A capsule filling machine |
| 07/20/2005 | EP1553909A2 Quick dissolve compositions and tablets based thereon |
| 07/20/2005 | EP1553904A2 Topical patch preparation kit containing a delayed-type hypersensitivity inducer |